This innovative approach paves the way for targeting of non-immunogenic intracellular oncoproteins displayed by MHC molecules on the tumor cell surface, potentially expanding the range of targetable antigens.156 Moreover, CAR-T cells targeting both GD2 and the immune checkpoint inhibitor B7H3 (CD276) have shown antitumoral effects in mouse models, with improved metabolic function and reduced risk of neurotoxicity.157 Combination treatment of dinutuximab with chemotherapeutic drugs is also under investigation. The gene discussed is CD276; the disease is neoplasm.